HEK293 Human TRPA1 Stable Cell
Item | Cat# | Price |
Stable Cell Line | SNB-I-0003A | $19,800 |
Compound Test Services | CT-001 | $1,850 per 384w plate (Up To 16 cpds Dose) |
Product Description
Transient Receptor Potential Ankyrin subtype 1 (TRPA1) is a member of the TRP channel family, functioning as a non-selective cation channel primarily expressed in sensory neurons. It is activated by a wide range of noxious stimuli, including reactive electrophiles, environmental irritants (such as mustard oil and cinnamaldehyde), cold temperatures, and mechanical stress. TRPA1 plays a crucial role in mediating pain, itch, and inflammatory responses by detecting chemical and physical irritants and triggering neuronal excitation. Beyond the nervous system, TRPA1 is also found in various non-neuronal cells, contributing to vascular tone regulation and inflammatory signaling. Because of its involvement in chronic pain, asthma, and inflammatory diseases, TRPA1 has become a key therapeutic target for developing analgesic and anti-inflammatory drugs.
Screeningbio’s TRPA1 cell line stable express non-tag full length human TRPA1 receptor in HEK293 cell. When activated, TRPA1 cell line response to extracellular stimuli and result in channel opening and calcium influx. Increase of intercellular calcium was detected by calcium sensitive dye.
Product Specifications
Target Type | Ion Channel |
Species | Human |
HGNC Symbol | TRPA1 |
Accession Number | NM_007332 |
Parental Line | HEK293 |
Lot# | See Vial |
Storage | Liquid Nitrogen |
Data
![Human TRPA1 Blocker Assay. HEK293 Human TRPA1 cells were seeded in 384-well plate and incubated at 37oC in 5% CO2 incubator for 24 hours before running the assay. The cells were treated with the reference blockers, and stimulated by activator. The assay was run based on FLIPR Calcium assay protocol. Non-linear regression was used to plot activity changes vs. [Compound, M], and EC50 /IC50 values were determined, using GraphPad Prism software.](https://static.wixstatic.com/media/56275b_892cc5aedb784c689c4a4963a6794ad5~mv2.png/v1/fill/w_76,h_75,al_c,q_85,usm_0.66_1.00_0.01,blur_2,enc_auto/56275b_892cc5aedb784c689c4a4963a6794ad5~mv2.png)
Target Background
The transient receptor potential ankyrin 1 (TRPA1) is a non-selective cation channel belonging to the TRP superfamily and is the sole member of the TRPA subfamily in mammals. TRPA1 is primarily expressed in nociceptive sensory neurons of the dorsal root, trigeminal, and nodose ganglia, where it functions as a polymodal sensor for environmental and endogenous irritants. It is activated by a wide range of electrophilic compounds such as allyl isothiocyanate (from mustard oil), cinnamaldehyde, allicin, and acrolein, which covalently modify cysteine residues in its N-terminal ankyrin repeat domain. In addition, TRPA1 can be activated by cold temperatures (<17 °C), mechanical stress, and oxidative or inflammatory mediators.
Upon activation, TRPA1 allows calcium and sodium influx, leading to membrane depolarization and initiation of pain and inflammatory signaling. The calcium influx further amplifies TRPA1 activity through positive feedback mechanisms, contributing to neurogenic inflammation and hypersensitivity. TRPA1 is also expressed in non-neuronal tissues, including airway epithelium, vascular endothelium, and immune cells, where it participates in airway irritation, vasodilation, and inflammatory responses.
Dysregulation of TRPA1 is associated with chronic pain, asthma, migraine, and inflammatory diseases. Because of its broad chemical sensitivity and involvement in nociception, TRPA1 is considered a key “chemosensor” in the peripheral nervous system and a promising therapeutic target for treating chronic cough, neuropathic pain, and inflammatory conditions.